scholarly journals Actions of colony-stimulating factor 3 on the maturing oocyte and developing embryo in cattle

2020 ◽  
Vol 98 (4) ◽  
Author(s):  
Elizabeth A Jannaman ◽  
Yao Xiao ◽  
Peter J Hansen

Abstract Colony-stimulating factor 3 (CSF3), also known as granulocyte colony-stimulating factor, is used to reduce the incidence of mastitis in cattle. Here, we tested whether recombinant bovine CSF3 at 1, 10, or 100 ng/mL acts on the bovine oocyte during maturation or on the developing embryo to modify competence for development and characteristics of the resultant blastocyst. For experiment 1, oocytes were matured with or without CSF3. The resultant embryos were cultured in a serum-free medium for 7.5 d. There was no effect of CSF3 on cleavage or on development to the blastocyst stage except that 100 ng/mL reduced the percent of putative zygotes and cleaved embryos becoming blastocysts. Expression of transcripts for 93 genes in blastocysts was evaluated by RT-PCR using the Fluidigm platform. Transcript abundance was affected by one or more concentrations of CSF3 for four genes only (CYP11A1, NOTCH2, RAC1, and YAP1). For experiment 2, cumulus-oocyte complexes (COC) were fertilized with either X- or Y-sorted semen. Putative zygotes were cultured in medium containing CSF3 treatments added at the beginning of culture. There was no effect of CSF3, sex, or the interaction on the percent of putative zygotes that cleaved or on the percent of putative zygotes or cleaved embryos becoming a blastocyst. For experiment 3, CSF3 was added from day 4 to 7.5 of development. There was no effect of CSF3 on development to the blastocyst stage. Transcript abundance of 10 genes was increased by 100 ng/mL CSF3, including markers of epiblast (NANOG, SOX2), hypoblast (ALPL, FN1, KDM2B, and PDGFRA), epiblast and hypoblast (HNF4A) and trophectoderm (TJAP1). Results are indicative that concentrations of CSF3 higher than typical after therapeutic administration can reduce oocyte competence and act on the embryo to affect characteristics of the blastocyst.

2020 ◽  
Vol 32 (2) ◽  
pp. 147
Author(s):  
E. Jannaman ◽  
Y. Xiao ◽  
P. Hansen

Colony-stimulating factor 3 (CSF3), also known as granulocyte colony-stimulating factor, has been reported to improve blastocyst yield when administered during oocyte maturation in the pig and to increase pregnancy outcomes in specific IVF patient populations when infused transvaginally. Here, we tested whether recombinant bovine CSF3 can act on the bovine oocyte during maturation or on the developing embryo to modify competence for development to the blastocyst stage. For Experiment 1, oocytes were matured with 0, 1, 10, or 100ngmL−1 of CSF3. Oocytes were then fertilised and embryos were cultured in serum-free medium for 7.5 days. There was no effect of CSF3 on cleavage rate or on development to the blastocyst stage except that 100ngmL−1 reduced (P=0.0366) the percentage of putative zygotes (P=0.0366) and cleaved embryos (P=0.0254) becoming blastocysts. Expression of transcripts for 93 genes in blastocysts was evaluated by RT-PCR using the Fluidigm platform. Transcript abundance was affected (P<0.05) by one or more concentrations of CSF3 for 4 genes only (CYP11A1, NOTCH2, RAC1, and YAP1). For Experiment 2, cumulus-oocyte complexes were fertilised with either X- or Y-sorted semen for 18-22h. Putative zygotes were cultured in medium containing 0, 1, 10, or 100ngmL−1 of CSF3. There was no effect of CSF3, sex, or the interaction on the percentage of putative zygotes that cleaved or on the percentage of putative zygotes or cleaved embryos becoming blastocysts. Gene expression was not determined. For Experiment 3, CSF3 (0, 1, 10, and 100ngmL−1) was added from Day 4 to 7.5 of development. Again, there was no effect of CSF3 on development to the blastocyst stage. Transcript abundance for a total of 10 genes was increased (P<0.05) by 100ngmL−1 of CSF3, including markers of epiblast (NANOG, SOX2), hypoblast (ALPL, FN1, KDM2B, and PDGFRA), both epiblast and hypoblast (HNF4A), and trophectoderm (TJAP1). Results are indicative that high concentrations of CSF2 can reduce oocyte competence and act on the embryo to affect characteristics of the blastocyst. Support was provided by the Elanco and Larson Endowment Fund.


2021 ◽  
Vol 9 (8) ◽  
pp. e003154
Author(s):  
Paolo Bossi ◽  
Cristina Gurizzan ◽  
Luigi Lorini ◽  
Pierluigi di Mauro ◽  
Chiara Sardini ◽  
...  

Myeloid growth factors, either granulocyte colony-stimulating factor (CSF) or granulocyte-macrophage CSF, are widely used to reduce the incidence and severity of chemotherapy-induced neutropenia by prophylactic or therapeutic administration. However, their activity in the novel therapeutic regimens, which often rely on the association between immunotherapy and chemotherapy, has not been thoroughly characterized yet. This paper presents some of the preclinical and clinical research regarding the putative interplay between myeloid growth factors and the immune system, advocating further studies to elucidate their potential positive or negative consequences on the outcomes when administered with immunotherapeutic agents.


2003 ◽  
Vol 47 (12) ◽  
pp. 3688-3693 ◽  
Author(s):  
Alieke G. Vonk ◽  
Mihai G. Netea ◽  
Johan H. van Krieken ◽  
Paul E. Verweij ◽  
Jos W. M. van der Meer ◽  
...  

ABSTRACT The aim of the present study was to assess the influence of immunomodulation of host defense with recombinant murine granulocyte colony-stimulating factor (rmG-CSF) on intra-abdominal abscesses caused by Candida albicans. Mice received prophylaxis or therapy with 1 μg of rmG-CSF/day in the presence or absence of antifungal treatment consisting of amphotericin B (0.75 mg/kg of body weight/day) or fluconazole (50 mg/kg/day). The number of Candida CFU in abscesses was significantly reduced (P < 0.05) in mice receiving rmG-CSF prophylaxis (day −1 or day −1 through 2) compared with controls on day 8 of infection. Administration of rmG-CSF therapy alone (for 5 days starting on day 4 of infection) had no influence on the number of Candida CFU in abscesses. Amphotericin B treatment was significantly more effective than fluconazole treatment (3.41 log CFU/abscesses; 95% confidence interval [CI], 3.17 log CFU/abscesses; 3.65 versus 3.90 log CFU/abscesses; 95% CI, 3.66 log CFU/abscesses, 4.16 log CFU/abscesses; P < 0.05). Therapeutic administration of rmG-CSF in conjunction with an antifungal agent showed a tendency towards a further reduction of Candida CFU in abscesses than antifungal treatment only. In conclusion, in this experimental model of intra-abdominal Candida abscesses, rmG-CSF administration did not have a detrimental influence on the course of infection. Amphotericin B treatment was most effective, and additional rmG-CSF therapy did not antagonize the effect of antifungal treatment. In contrast, addition of rmG-CSF therapy to antifungal treatment might further enhance the beneficial effect of the antifungal agent.


2008 ◽  
Vol 35 (S 01) ◽  
Author(s):  
T Frank ◽  
K Meuer ◽  
C Pitzer ◽  
J Schulz ◽  
M Bähr ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document